Sector News

Moderna’s vaccines head steps down as readouts near

March 7, 2018
Life sciences

Giuseppe Ciaramella, the leader of Moderna Therapeutics’ infectious diseases business, has jumped to an as yet unnamed “stealth-mode biotech startup,” leaving a long list of clinical programs behind, according to healthcare news site STAT.

As CSO of the vaccines business, Ciaramella was responsible for Moderna’s most advanced programs, including vaccines against CMV, HMPV/PIV3, influenza, Zika and chikungunya, as well as undisclosed targets under a Merck partnership.

Ciaramella joined the mRNA biotech back in 2014. He has about two decades of biopharma industry experience, having previously served at AstraZeneca, Boehringer Ingelheim, Pfizer and Merck, with a focus on antivirals and biotherapeutics.

He was tasked to lead Valera, part of the Moderna family, when the unicorn biotech launched it in early 2015 to focus exclusively on prophylactic and therapeutic vaccines against infectious diseases. But the biotech later ditched the venture-based R&D model in favor of a therapeutic area-oriented approach, bringing all four units, Valera included, under one single corporation.

Moderna actually used its mRNA-based H10N8 flu vaccine as the first clinical project to lay the groundwork for its entire pipeline. At least according to CMO Tal Zaks, M.D., Ph.D., interim data from a phase 1 study released last April “provide important validation of our core mRNA platform.”

In 2016, the company received an award of up to $125 million from the Biomedical Advanced Research and Development Authority for the development of Zika vaccines. The more advanced Zika candidate it in-licensed, mRNA-1325, is expected to have a phase 1 readout later this year, and the company also has a preclinical backup made of its proprietary formulations.

Other than those programs, Moderna pushed a chikungunya vaccine into the clinic last August with financial backing from the Department of Defense’s Defense Advanced Research Projects Agency. It also advanced a CMV vaccine and a HMPV/PIV3 combination vaccine into human testing in November and December, respectively.

The news, first broken by STAT, could add to questions around the biotech’s technology. It comes after a trio of top R&D departures from the biotech last year: Matthew Staton, Ph.D., who was head of chemistry; Barry Ticho, M.D., Ph.D., who once headed up cardiovascular and metabolic diseases; and Arian Pano, Ph.D., who led clinical development for rare diseases.

Despite the doubts, Moderna still retains the charm to attract big investments, having just raised $500 million in a series G round to reach a value of $7 billion.

It is unclear why Ciaramella left, and Moderna didn’t immediately respond to a request for confirmation. Ciaramella’s LinkedIn page already shows him as the CSO of a “stealth mode biotech startup” since February. His name also disappeared from Moderna’s website.

By Angus Lui

Source: Fierce Pharma

comments closed

Related News

June 8, 2024

Lilly CFO leaves to join Alphabet

Life sciences

Anat Ashkenazi will leave Eli Lilly’s executive suite at the end of July to become CFO and senior vice president of Google and Alphabet. Ashkenazi has been CFO at Lilly since 2021 and originally joined the company in 2001. Over her 23-year career at the Indianapolis-based drugmaker, Ashkenazi also served as controller, CFO of Lilly Research Laboratories and as the finance chief for several global divisions within the company.

June 8, 2024

Edwards Lifesciences to cell Critical Care to BD

Life sciences

Edwards Lifesciences (NYSE: EW) announced it has entered into a definitive agreement to sell its Critical Care product group to BD (Becton, Dickinson and Company), in an all-cash transaction valued at $4.2 billion. With this agreement, Edwards is no longer pursuing the previously announced spin-off of Critical Care.

June 8, 2024

Danaher names Martin Stumpe as chief data and AI officer

Life sciences

The company, which owns diagnostics and life sciences businesses including Beckman Coulter and Cepheid, said the appointment reflects its increasing investment in AI as “a driving force for innovation and productivity.” Danaher is focused on AI by also spending on its internal capabilities and partnering with academic groups.

How can we help you?

We're easy to reach